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HEPARIN VERSUS ASPIRIN AFTER RECOMRINANT’ 
TISSUE PLASMINOGEN ACTIVATOR THERAPY IN 
MYocARDIAL~mcTIo~ARANDoMIzET)TRIAL 
Judith Hsia, M.D., F.AC.C., 
C., Bernard Chaitman, M.D., 
FJLCC., Robert Roberts, M.D., F.A.C.C., Neil S. Neiman, 
M.D., F.A.C.C.. George Washington University, Washington, 
DC. 
After lytic therapy with tissue plasminogen activator 
(VA) adjunetive heparin and/or aspirin are used to 
max+nize patency aud preveen! reoeelusion, but no 
randomized trial has evaluated their comparative efficacy for 
those purposes nor assessed their relative impact on 
hemorrhagic complications. Accordingly a multicenter trial 
(George Washington, St. Louis and Baylor) has randomized 
190 pts of a projected 200 pt sample size. Acute MI pts 
Iwith l/2 - 6h of pain and 2 lmm ST elevation in 2 
contiguous leads received TPA, 100 mg, over 6h and either 
heparin (begun after the start of TPA infusion as SOOOU 
bolus, then lOOOU/hr ultimately titrated to FTT 1 l/2 - 2 X 
control for 7 days) or aspirin (80 mg po at start of TPA, 
then daily for 7 days). 
Initial patency is established by angiogram 7-24h after 
TPA start; reocclusion identified by repeat angiography at 7- 
10 days. No angioplasty is done except for recurrent 
ischemis. Hemorrhagic events and transfusion needs are 
recorded at clinical sites; angiographic endpoints are 
established in a core lab blinded to film sequence and drug 
assignment. Endpoint data analysis will be completed for 
presentation by March 1990. 
, Yoram Maarvi, MD, Yaacov 
Matzner, MD, Dan Gilon, MD, A. Teddy Weiss, 
M.D, FACC, Mervyn S. Gotsman, MD, FACC. 
Reocclusion following thrombolysis is 
possibly caused by a prothrombotic state. We 
compared the response to anticoagulation of 
fifty patients (pts) who had been given 
streptokinase (SK) and subsequent 
anticoagulation for acute myocardial infarction 
(A.!?+I.) {group 1) with that of 35 pts treated 
wftk anticoagulants without prior thrombolysis, 
eitkor for A.M.I. or for other indications 
(gr ,up 2). Fts who had received SK required 
37,' 55kl516 (mean&SEM) units of heparin per day 
to achieve the desired A$T!I!, compared with 
30,294&1089 units per day in pts without 
antecedent thrombolysis (PcO.OOl), and were 
treated 4.7-r-0.4 days with heparin until 
achievement of adequate anticoagulation, as 
compared with 3.320.2 days in the control group 
(P=O.Ol). Despite their higher heparin 
requirement, group 1 pts attained a lower APTT 
value than the control subjects (87.225.0 Vs. 
100.7f5.9 seconds, (P=O.O8). Group 1 pts 
reguired 5.020.3 days to reach anticoagulation 
with warfarin, as contrasted with 4.120.2 days 
in group 2 (PrD.05). We suggest that following 
thrombolytic treatment in A.M.I. there is 
partial resistance to anticoagulation: 
anticoagulant therapy should be adjusted 
accordingly, since inadequate anticoagulation 
may be responsible for the process of 
reocclusion and recurrent ischemia. 
Joseph D B&b, Donald S Bairn, James 
rt Roberts, David 0 Williams, San
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These data support a policy of “watchful waking” with coronary 
RESULTS OF A RANDOMIZED TRIAL COMPARING APSAC 
AND rTPA FOR THE PRESERVATION DF LEFT VENTRICULAR 
FONCTION AFTER ACUTE MYOCARDIAL INFARCTION. 
Jacques Machecourt, M.D., Jean Cassagnes, M.D., Jean P. 
Basssnd, M.D., Jean R. Lussan, M.D., Thierrv Anquenot, M.D., 
Bernard Bertrand, M.D%, Frangois Schiele, M;D., Sean E; Wolf; 
M.D., Jean Maublant, M.D., University Hospital Grenoble 
38043 FRANCE 
180 patients with a first acute MI were randomly included in 
a double blind double dummy multicenter study comparing 
APSAC (30 mg IV over 5 minutes) and rTPA (IO mg in 
bolus, and 90 mg over 180 min). Only pts aged 70 years. or 
less, with clinical and ECG evidences of MI and admitted 4 
hours cr less after the onset of chest pain, were inclucied. 
Global and regional LV fonction were assessed from a LV 
angiography (angio) performed between day 5 and day 7, plus 
a radionuclide angiography (RN) performed 3 weeks later. 
Each parameter was blindly analyzed by two independant 
observers. 
Results : ._--___ _ 
- there was no difference for baseline data (age 54 5. 11 yrs, 
onset of treatment 170 t 50 min after TO), and clinkal data 
(in hospital mortality rTPA 7 pts vs APSAC 5 pts, bleeding 
rTPA 9 pts, vs APSAC 11 pts). 
;,mti;j fonction and angio results : m (+ 95 % confidence . . 
rTPA APSAC P 
Patency Rat~*~~NS 
Angio E.F. .52 t.49 - .55) .50 (.4E - .53) NS 
Asynerqic scnre 10.9 (9 - 12.7) 11.7 (IfI - 134) NS 
RN EF .48 t.46 - ,501 .48 i.46 - .SO) NS 
- Subf,roup analysis for anterior MI (n = 76) and posterior MI 
(n = 99) showed no statistical difference. 
Conclusion : there is no, or only minimal differences in term 
of preservation of LV fonction, between APSAC and rTPA 
administrated at the early stage of a MI. 
